{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:36:45Z","timestamp":1787773005938,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n \n Cutaneous leishmaniasis (CL) infection is caused by the\n Leishmania major (L. major)<\/jats:italic>\n parasite and affects 1.5 to 2 million people worldwide each year. Although research into vaccines and antiparasitic drugs has been somewhat successful, their adverse effects include high toxicity, prolonged regeneration, and scarring. This has highlighted the importance of research to replace natural products with antibacterial and antioxidant properties, such as vegetable extracts and oils. Since, the anti-leishmaniasis effect of each of the components of Shirvan herbal ointment (aloe vera, Brazembel,\n Nigella sativa<\/jats:italic>\n , propolis, lavender, and olive oil) has been separately studied and confirmed, it seems that the combination of these components can have an increasing anti-\n leishmanial<\/jats:italic>\n effect to treat CL. Therefore, this study investigated the therapeutic impact of Shirvan herbal ointment on Iranian patients with leishmaniasis in comparison with glucantime (meglumine).\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n Sixty patients with leishmaniasis were divided into the control and test groups. The control and test groups received intralesional glucantime and Shirvan herbal cream (two times daily), respectively.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The size mean of the lesion was 51.5 \u00b1 32.5 before and 11.11 \u00b1 16.28 after treatment in the control group and 50.8 \u00b1 31.2 before and 0.0 \u00b1 0.0 after treatment in the test group. In addition, the period mean of treatment was 43.9 \u00b1 14.4 days and 30.5 \u00b1 7.4 days in the control and test groups, respectively. There was a significant difference in lesion size between the two groups after treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Data suggested that Shirvan herbal ointment can be an alternative drug in the treatment of human CL.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/abr.abr_243_23","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:01:29Z","timestamp":1724817689000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Therapeutic Effect of Shirvan Herbal Ointment on Human Cutaneous Leishmaniasis Compared with Glucantime"],"prefix":"10.4103","volume":"13","author":[{"given":"Maryam","family":"Aghaei","sequence":"first","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Aghaei","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran"},{"name":"Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghelichzadeh","sequence":"additional","affiliation":[{"name":"Department of Parasitology, School of Medicine, Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis (INRCL) and Toxoplasmosis (INRCT), Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Ansari","sequence":"additional","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Fakhar","sequence":"additional","affiliation":[{"name":"Department of Parasitology, School of Medicine, Toxoplasmosis Research Center, Communicable Diseases Institute, Iranian National Registry Center for Lophomoniasis (INRCL) and Toxoplasmosis (INRCT), Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Mohsen","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabihollah","family":"Shahmoradi","sequence":"additional","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Hossein","family":"Hejazi","sequence":"additional","affiliation":[{"name":"Department of Parasitology and Mycology, Skin Diseases and Leishmaniasis Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br Med Bull"},{"key":"R2-20240830","first-page":"1","article-title":"Epidemiology and ecology of leishmaniasis","author":"Inceboz","year":"2019","journal-title":"Current topics in neglected tropical diseases"},{"key":"R3-20240830","first-page":"143","article-title":"Human cutaneous leishmaniosis in Iran, up to date-2019","volume":"15","author":"Razavi","year":"2021","journal-title":"J Arthropod Borne Dis"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0035-9203(60)90057-2","article-title":"Stages in the life-cycle of Leishmania donovani","volume":"54","author":"Pulvertaft","year":"1960","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: Current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"R6-20240830","first-page":"25","article-title":"The therapeutic effect of ozonated olive oil plus glucantime on human cutaneous leishmaniasis","volume":"22","author":"Aghaei","year":"2019","journal-title":"Iran J Basic Med Sci"},{"key":"R7-20240830","first-page":"18","article-title":"The antileishmanial activity of Aloe vera leaf exudates: In vitro and in vivo","volume":"22","author":"Shamsi","year":"2019","journal-title":"Iran J Dermatol"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1021\/np010032f","article-title":"Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1, 2-quinones from Perovskia abrotanoides: New source of tanshinones","volume":"64","author":"Sairafianpour","year":"2001","journal-title":"J Nat Prod"},{"key":"R9-20240830","first-page":"1239","article-title":"Antileishmanial activity of Nigella sativa extract against Leishmania major: An in vitro study","volume":"7","author":"Bafghi","year":"2015","journal-title":"J Chem Pharm Res"},{"key":"R10-20240830","first-page":"301","article-title":"Comparison of thymus vulgaris (thyme), achillea millefolium (yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb\/c mice","volume":"45","author":"Nilforoushzadeh","year":"2008","journal-title":"J Vector Borne Dis"},{"key":"R11-20240830","first-page":"622","article-title":"Antileishmanial activity of lavandula angustifolia and rosmarinus officinalis essential oils and nano-emulsions on leishmania major (MRHO\/IR\/75\/ER)","volume":"12","author":"Shokri","year":"2017","journal-title":"Iran J Parasitol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"837","DOI":"10.12991\/mpj.2017.6","article-title":"The therapeutic effects of olive leaf extract on leishmania major infection in BALB\/c mice","volume":"21","author":"Kheirandish","year":"2017","journal-title":"Marmara Pharm J"},{"key":"R13-20240830","first-page":"483","article-title":"In vivo anti-leishmanial activity of concocted herbal topical preparation against leishmania major (MRHO\/IR\/75\/ER)","volume":"67","author":"Saberi","year":"2021","journal-title":"Ann Parasitol"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0972-9062.112532","article-title":"Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran","volume":"50","author":"Karami","year":"2013","journal-title":"J Vector Borne Dis"},{"key":"R15-20240830","first-page":"73","article-title":"Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: A randomized, double-blind, controlled clinical trial","volume":"4","author":"Firooz","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2478\/s11686-020-00205-2","article-title":"In vitro anti-leishmanial assessment of some medicinal plants collected from Al Qassim, Saudi Arabia","volume":"65","author":"Al Nasr","year":"2020","journal-title":"Acta Parasitologica"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/2211352517666190123113843","article-title":"Novel strategies and pharmaceutical agents for the treatment of leishmaniasis: A review","volume":"18","author":"Nilforoushzadeh","year":"2020","journal-title":"Anti-Infective Agents"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_243_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:15:26Z","timestamp":1787771726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_243_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":17,"URL":"https:\/\/doi.org\/10.4103\/abr.abr_243_23","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-07-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}